ブリュッセル + 32.2.645.14.52

Justine Naessens advises clients on EU and national regulatory matters in the life sciences area, including biotechnology, pharmaceuticals, medical devices, and food and cosmetics.

Justine assists companies in the entire life cycle of products from early development stages to manufacturing, marketing, post-marketing, and pricing and reimbursement issues, as well as in M&A and other corporate transactions. Her legal studies included a concentration in technology, intellectual property, and medical law. Justine often assists clients in connection with regulatory matters involving the use of digital technologies in the health care sector, such as the classification of software as a medical device, the use of artificial intelligence (AI) in product development, and associated privacy (General Data Protection Regulation [GDPR]) requirements.


  • Riverside acquires CRIO, Inc.Jones Day advised The Riverside Company in the acquisition of CRIO, Inc., a leading provider of eSource and other eClinical software for clinical trial sites, CROs and the pharmaceutical/biotech market.
  • Reneo Pharmaceuticals announces reverse merger with OnKureJones Day is representing Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) in an all-stock reverse merger between Reneo and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company valued at $170 million that is focused on the development of novel precision medicines in oncology.
  • Astellas acquires Iveric bioJones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.